Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Bought by Marshall Wace LLP

Marshall Wace LLP lifted its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 19.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 971,143 shares of the company’s stock after buying an additional 159,791 shares during the quarter. Marshall Wace LLP owned approximately 2.09% of Pacira BioSciences worth $27,784,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. ICA Group Wealth Management LLC purchased a new stake in Pacira BioSciences in the 4th quarter worth $30,000. GAMMA Investing LLC increased its stake in shares of Pacira BioSciences by 229.6% during the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after purchasing an additional 932 shares in the last quarter. Park Place Capital Corp purchased a new stake in shares of Pacira BioSciences during the second quarter worth about $46,000. Innealta Capital LLC acquired a new position in shares of Pacira BioSciences during the 2nd quarter worth about $50,000. Finally, nVerses Capital LLC lifted its stake in Pacira BioSciences by 800.0% in the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock valued at $51,000 after buying an additional 1,600 shares in the last quarter. 99.73% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Jonathan Slonin sold 2,836 shares of the business’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $28.25, for a total value of $80,117.00. Following the sale, the insider now directly owns 95,557 shares in the company, valued at approximately $2,699,485.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Pacira BioSciences news, insider Jonathan Slonin sold 2,836 shares of Pacira BioSciences stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $28.25, for a total transaction of $80,117.00. Following the completion of the sale, the insider now directly owns 95,557 shares in the company, valued at $2,699,485.25. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Frank D. Lee acquired 8,264 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was bought at an average price of $12.10 per share, for a total transaction of $99,994.40. Following the completion of the acquisition, the chief executive officer now owns 107,784 shares in the company, valued at approximately $1,304,186.40. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 11,176 shares of company stock valued at $136,240 and have sold 4,281 shares valued at $105,494. Corporate insiders own 6.40% of the company’s stock.

Pacira BioSciences Price Performance

Shares of PCRX stock opened at $14.33 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 6.82 and a quick ratio of 5.70. The company has a market capitalization of $667.00 million, a PE ratio of 10.02 and a beta of 0.84. The firm’s 50-day moving average is $16.06 and its two-hundred day moving average is $23.64. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings results on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.53 by $0.11. The firm had revenue of $178.02 million for the quarter, compared to analyst estimates of $173.31 million. Pacira BioSciences had a net margin of 9.21% and a return on equity of 13.22%. Analysts predict that Pacira BioSciences, Inc. will post 2.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PCRX has been the subject of a number of research analyst reports. Jefferies Financial Group increased their target price on Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday. Barclays downgraded Pacira BioSciences from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $38.00 to $25.00 in a research note on Wednesday, July 3rd. Royal Bank of Canada cut shares of Pacira BioSciences from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $37.00 to $14.00 in a research note on Monday, August 12th. Piper Sandler lowered shares of Pacira BioSciences from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $42.00 to $11.00 in a report on Monday, August 12th. Finally, JPMorgan Chase & Co. reissued an “underweight” rating and issued a $10.00 price target (down from $45.00) on shares of Pacira BioSciences in a research note on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, Pacira BioSciences presently has a consensus rating of “Hold” and an average target price of $24.10.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.